Key result
Amiodarone pulmonary toxicity requires drug withdrawal and corticosteroids, with abnormal pretreatment PFTs indicating higher risk.
Why the study?
Pulmonary toxicity is the most serious potential common side effect of amiodarone, but there is no ideal means for monitoring or preventing it.
What are the manifestations, pathophysiology, and management of amiodarone pulmonary toxicity?
Design
Review
Authors
Loading...
Warrants prompt recognition and discontinuation in symptomatic patients; confirms lipid storage disorder as underlying pathophysiology.
What are the manifestations, pathophysiology, and management of amiodarone pulmonary toxicity?
Amiodarone pulmonary toxicity is a serious complication requiring drug withdrawal and potentially corticosteroids, with pretreatment pulmonary function abnormalities potentially identifying high-risk patients.
Kudenchuk et al. (1986) conducted a review in Amiodarone pulmonary toxicity. Amiodarone was evaluated. Amiodarone pulmonary toxicity presents as interstitial pulmonary fibrosis and is managed by drug withdrawal and corticosteroids, with pretreatment pulmonary function abnormalities indicating higher risk.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: